<DOC>
	<DOCNO>NCT01269710</DOCNO>
	<brief_summary>The purpose study get good understanding side effect burden identify predictor psychotic , mood aggressive disorder child adolescent . The study 's primary aim identify genetic risk factor weight gain metabolic abnormality .</brief_summary>
	<brief_title>Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth ( Satiety ) Study</brief_title>
	<detailed_description>Participants evaluate biological genetic risk factor nutritional metabolic adverse effect associate SGAPs ( second generation antipsychotic ) 4 visit 12 week . Participants also evaluate month 6 , 9 , 12 . This study involve treatment participant . Treatment subject enrol study determine clinician remain unaffected participation observational minimal risk study . All participant prescribe risperidone ( Risperdal ) duration study participation dos range 0.25mg 6mg daily 52 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Schizotypal Personality Disorder</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Patients age 3 19 ( time consent ) 2 . Clinical diagnosis psychotic disorder ( i.e. , schizophrenia , schizoaffective disorder , schizophreniform disorder , psychotic disorder otherwise specify prodromal schizophrenia ( define Scale Prodromal Symptoms ( SOPS : Miller 1996 ) ) , mood disorder ( i.e. , bipolar disorder , major depressive disorder , depressive disorder otherwise specify , mood disorder otherwise specify ) autism spectrum disorder . 3 . Subjects consider treatment second generation antipsychotic ( SGAPs ) physician evaluate him/her 4 . Subjects either A ) antipsychotic na√Øve start SGA within past 2 week , B ) start new antipsychotic within past 2 week ( specifically within 2 week first blood draw ) , 1 . Individuals young 3 year old 19 year 11 month ( time consent ) 2 . Personal history comorbid eat disorder 3 . Active hyper/hypothyroidism 4 . Pregnancy 5 . Severe medical disorder ( i.e. , AIDS , cancer , sepsis , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Second Generation Antipsychotics</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective</keyword>
	<keyword>Schizophreniform</keyword>
	<keyword>Psychosis NOS</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Weight</keyword>
	<keyword>Autism</keyword>
</DOC>